Record Q3 revenue grew 23% year-over-year, driven by strong AI-enabled drug discovery and diagnostics. Raised fiscal 2026 guidance, expecting 21% growth and adjusted EBITDA breakeven in Q4. Triple-digit AI order growth is projected to continue into 2027, supported by robust customer demand and platform scalability.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.